| Bioactivity | Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a Ki value of 0.32 nM. Eribaxaban reduces thrombus formation[1][2]. |
| Target | Ki: 0.32 nM (FXa) |
| In Vivo | Eribaxaban (0.4, 0.9, 4.3 mg/kg; p.o.) 可减少富含血小板的血栓形成[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 536748-46-6 |
| Formula | C24H22ClFN4O4 |
| Molar Mass | 484.91 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eriksson BI, et al. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22. [2]. Karnicki K, et al. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis. Thromb Haemost. 2008 Apr;99(4):759-66. |
Eribaxaban
CAS: 536748-46-6 F: C24H22ClFN4O4 W: 484.91
Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a Ki value of 0.32 nM. Eribaxaban reduces t
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.